Lead sponsor
EIP Pharma Inc
7 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
7
Trials led
1
Ongoing
489
Total enrollment
110
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
7
Trials by status
Active, not recruiting
1
Completed
6
Trials led
TrialEligibility highlightPhaseStatusEnrollment
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy BodiesDementia with Lewy bodiesPh 2Completed159
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy BodiesDementia with Lewy bodiesPh 2Completed26
Clinical Study of Neflamapimod in Patients With Primary Progressive AphasiaCDR global 0.5Ph 2Active, not recruiting20
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild ADMCI due to ADPh 2Completed16
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)Alzheimer's diseasePh 2Completed16